

arisaph

creating smart medicines

MANAGEMENT TEAM

CHRISTOPHER P. KIRITSY

 Co-founder
 President and Chief Executive Officer

WILLIAM BACHOVCHIN, PH.D.

 Co-founder, Executive Vice President
 and Chief Scientific Officer

CLAUDE BENEDICT, M.D., PH.D.

Senior Vice President, Drug Development

JACK LAI, PH.D.

Director of Medicinal Chemistry

DAVID SANFORD, PH.D.

Director of Protein Chemistry

JOSEPH SUAREZ

Director of Business Planning and Operations

EXECUTIVE COMMITTEE OF BOARD OF DIRECTORS

MICHAEL JAHARIS

Co-Founder

KEVIN FERRO

 Chairman
 CEO and Chief Investment Officer
 Ferro Capital LLC & Oikos Advisors LLC

CHRISTOPHER P. KIRITSY

 Co-founder
 President and Chief Executive Officer

WILLIAM BACHOVCHIN, PH.D.

 Co-founder, Executive Vice President
 and Chief Scientific Officer

ROBERT BALDINI

Consultant, Corporate Development

COMPANY VALUES

Advancing human health
Results and peak performance
Innovation is our cornerstone
Sense of urgency and passion
Act from understanding
People first
Honesty and integrity

COMPANY BACKGROUND

Arisaph Pharmaceuticals, Inc. is an emerging drug discovery, biopharmaceutical company focused on developing novel therapies for cancer, cardiovascular disease and diabetes. The company utilizes proprietary drug discovery platforms to develop differentiated drugs that are highly potent and act selectively on validated targets. Arisaph currently has seven active drug discovery programs in various stages of preclinical development.

Arisaph, which was co-founded in 1999 by Dr. William Bachovchin (Professor of Biochemistry at Tufts University Medical School), Christopher Kiritsy (former EVP Corporate Development and CFO of Kos Pharmaceuticals, Inc.) and Michael Jaharis (Principal founder of Kos and former CEO of Key Pharmaceuticals), has an experienced board and management team with a proven record of building highly successful fully integrated pharmaceutical enterprises. Kos, which was acquired by Abbott Laboratories for \$4 billion in 2006, pioneered the development of HDL cholesterol therapies with the advent of Niaspan[®] and became the fastest growing pharmaceutical company in 2005, according to *Fortune Magazine*.

OUR PIPELINE

DESCRIPTION	INDICATION	HIT-TO-LEAD	PRE-CLINICAL EFFICACY	NON-CLINICAL TOXICOLOGY	PHASE I CLINICAL
DPP-IV INHIBITORS	DIABETES				
GLP-1 ANALOG	DIABETES				
TUMOR ACTIVATED PRO SOFT DRUGS**	CANCER				
REV D-4*	ATHEROSCLEROSIS				
NIACIN ANALOG*	HDL MODULATION				
ORAL GLP-1	DIABETES				
LIPASE INHIBITOR*	HDL MODULATION				

* Partnership with Abbott Laboratories / ** Research collaboration with Fox Chase (product rights belong to Arisaph)

DRUG DISCOVERY PLATFORMS

Specificity Profiling Platform (SPP)

Specificity profiling is a proprietary drug discovery platform that allows for rapid screening of the best inhibitors within a library of potential inhibitors. SPP can be broadly applied to modulate numerous proteases to expedite the drug design and discovery of potential compounds. SPP was successfully reduced to practice in designing Arisaph's smart DPP-IV inhibitors.



SCIENTIFIC ADVISORY BOARD

ANTONIO M. GOTTO, JR. M.D.
Dean of Weill Medical College of
Cornell University

DANIEL J. DRUCKER, M.D., FRCPC
Professor of Medicine
University of Toronto

VIJAY KUMAR KUCHROO, D.V.M., PH.D.
Professor of Neurology
Harvard University

RUDOLPH LEIBEL, M.D.
Professor of Pediatrics and Medicine at Columbia
University College of Physicians and Surgeons

JONATHAN CHENG, M.D.
Associates Member
Fox Chase Cancer Research Center

ALFRED GOLDBERG, PH.D.
Professor of Cell Biology
Harvard Medical School

ALAN R. TALL, M.D.
Professor of Medicine
Columbia University

INVESTORS

OIKOS INVESTMENTS PARTNERS, L.P.
(Investment vehicle of Michael Jaharis)

ABBOTT LABORATORIES

STONE LIFE SCIENCES, LTD

CONTACT INFORMATION

ARISAPH PHARMACEUTICALS, INC
75 Kneeland Street, 4th floor
Boston, MA 02111
tel 617.292.3322
fax 617.292.3309
www.arisaph.com

JOSEPH SUAREZ
Director of Business Planning and Operations
jsuarez@arisaph.com

Ultra-Smart Pro-Soft Drugs

The ultra-smart pro-soft drug discovery platform utilizes the in-depth understanding of enzyme substrate complexes to produce pro-soft drugs that act selectively and temporally on specific targets. The platform is applied to create compounds that are inactive *en route* to the target, hyper active at target site, and inactive on diffusing away. The discovery platform is extremely useful in developing targeted therapies for cancer.

PEP (Peptide Enhancing Platform) Drug Discovery

The PEP drug discovery technology can be selectively applied to render biologically active peptides stable to serine protease degradation, *in vivo*. This action effectively increases both the potency and the duration of action. Arisaph has successfully reduced to practice PEP in developing reverse D-4F, a novel apo A-1 mimetic peptide that showed significant regression of atherosclerosis in preclinical animal studies.

VISION AND STRATEGY

The vision of Arisaph is to build a fully-integrated pharmaceutical company, in which the Company commercializes its internally developed medicines through a specialty sales force. The Company's strategy is to utilize its formidable medicinal chemistry expertise to design best-in-class medicines acting on validated targets, which mitigates a certain amount of development risk. The Company's business development strategy seeks to leverage Arisaph's drug discovery capabilities through co-development/co-commercialization partnerships and research collaborations.

PARTNERSHIPS/COLLABORATIONS

The Company has established a drug discovery partnership with Abbott Laboratories, in which Arisaph designs novel compounds that raise HDL cholesterol or treat atherosclerosis. Additionally, the Company maintains a sponsored research collaboration with Fox Chase Cancer Center, where Fox Chase evaluates novel and innovative cancer compounds designed and synthesized by Arisaph. Last, through a license agreement with Tufts University, the Company has exclusive worldwide rights to several important *issued* patents in the diabetes area and to discoveries in the therapeutic *fields of interest*.

PRINCIPAL CORPORATE MILESTONES

- Founded the company in 1999 with seed capital from Michael Jaharis
- Completed \$16 million equity financing in February 2005
- Appointed Christopher Kiritsy as President and Chief Executive Officer
- Received issuance of broad use patent for DPP-IV inhibitors in type II diabetes
- Leveraged diabetes IP by establishing attractive cash generating non-exclusive license
- Established anti-cancer research collaboration with Fox Chase Cancer Center
- Presented preclinical data for rev D-4F showing significant plaque regression at 2005 AHA meeting
- Extended drug discovery partnership with Abbott for development of novel therapies for atherosclerosis
- Presented compelling efficacy data for ARI 2243 at ADA meetings in June 2007 and 2008
- Filed IND for ARI 2243 during first half of 2008
- Completed Phase Ia human safety for ARI 2243 in 2008